Biogen shares plunge after Alzheimer’s drug setback

Biotech giant halts late-stage trials as results disappoint

Pic: Getty
A sign for biotechnology company, Biogen, Inc. is seen on a building in Cambridge, Massachusetts, on March 18, 2017. / AFP PHOTO / DOMINICK REUTER (Photo credit should read DOMINICK REUTER/AFP/Getty Images)

Shares in Biogen plummeted yesterday after the biotechnology giant said that its experimental Alzheimer’s drug was unlikely to be effective and that it was halting its research, in another setback to efforts to find a therapy for the neurodegenerative ailment.

Shares dropped by ...